Trial Profile
A phase I trial to investigate CPC-201
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Donepezil/solifenacin (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Chase Pharmaceuticals
- 09 Dec 2015 New trial record